117 related articles for article (PubMed ID: 16996162)
1. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex.
Kuramoto Y; Nishikawa M; Hyoudou K; Yamashita F; Hashida M
J Control Release; 2006 Oct; 115(2):226-33. PubMed ID: 16996162
[TBL] [Abstract][Full Text] [Related]
2. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice.
Kuramoto Y; Kawakami S; Zhou S; Fukuda K; Yamashita F; Hashida M
J Control Release; 2008 Mar; 126(3):274-80. PubMed ID: 18237815
[TBL] [Abstract][Full Text] [Related]
3. Use of mannosylated cationic liposomes/ immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice.
Kuramoto Y; Kawakami S; Zhou S; Fukuda K; Yamashita F; Hashida M
J Gene Med; 2008 Apr; 10(4):392-9. PubMed ID: 18181219
[TBL] [Abstract][Full Text] [Related]
4. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
5. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages.
Yasuda S; Yoshida H; Nishikawa M; Takakura Y
Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296
[TBL] [Abstract][Full Text] [Related]
7. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
8. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice.
Hyoudou K; Nishikawa M; Kobayashi Y; Mukai S; Ikemura M; Kuramoto Y; Yamashita F; Hashida M
J Control Release; 2007 May; 119(1):121-7. PubMed ID: 17382424
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice.
Zhou S; Kawakami S; Yamashita F; Hashida M
Cancer Lett; 2010 Jan; 287(1):75-81. PubMed ID: 19660857
[TBL] [Abstract][Full Text] [Related]
12. TLR9-dependent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice.
Yoshida H; Nishikawa M; Yasuda S; Mizuno Y; Toyota H; Kiyota T; Takahashi R; Takakura Y
J Gene Med; 2009 Aug; 11(8):708-17. PubMed ID: 19462411
[TBL] [Abstract][Full Text] [Related]
13. Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages.
De Rosa G; De Stefano D; Laguardia V; Arpicco S; Simeon V; Carnuccio R; Fattal E
Eur J Pharm Biopharm; 2008 Sep; 70(1):7-18. PubMed ID: 18482831
[TBL] [Abstract][Full Text] [Related]
14. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
15. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
16. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs.
Novaković S; Stegel V; Kopitar A; Ihan A; Novaković BJ
Vaccine; 2007 Nov; 25(49):8241-56. PubMed ID: 17980936
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA.
Kim D; Kwon S; Ahn CS; Lee Y; Choi SY; Park J; Kwon HY; Kwon HJ
BMB Rep; 2011 Nov; 44(11):758-63. PubMed ID: 22118544
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses.
Whitmore MM; Li S; Falo L; Huang L
Cancer Immunol Immunother; 2001 Dec; 50(10):503-14. PubMed ID: 11776372
[TBL] [Abstract][Full Text] [Related]
19. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
[TBL] [Abstract][Full Text] [Related]
20. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
